Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA
Despite controversy, many studies have found no significant association between aspartame consumption and the incidence of different types of solid and hematologic malignancies.
Vitamin A supplementation likely does not reduce chemotherapy efficacy and, for many patients, is unlikely to cause harm.
Ponatinib is highly effective among patients with CML, but the optimal dose is still being determined. Current trials are evaluating an initial dose of 30 mg, with a reduction to 15 mg when a response is achieved.
Though some studies reported improvements in clinical outcomes and quality of life with vitamin C treatment, these findings have not been replicated in randomized controlled studies.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
More Articles by Andrea S. Blevins Primeau, PhD, MBA
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective